New drugs did not change overall glycemic control in U.S. patients with type 2 diabetes, study finds
The proportion of type 2 diabetes patients with HbA1c levels of 9% or greater or HbA1c between 8% and 9% increased from 2006 to 2013, while the proportion with an HbA1c less than 6% decreased.
Elevations in high-sensitivity troponin T or N-terminal pro-B-type natriuretic peptide were significantly associated with risk of cardiovascular death, myocardial infarction, and hospitalization for heart failure, while C-reactive protein was a less significant predictor.
The trial of semaglutide included 3,297 patients with type 2 diabetes, 83% of whom had established cardiovascular disease, chronic kidney disease, or both.
Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patients
More than 20% of patients with type 2 diabetes received treatment more intensive than that recommended by HbA1c-based guidelines, a study of Medicare patients found.
Whether to screen a patient for type 2 diabetes is the focus of a Beyond the Guidelines feature in the Oct. 4 Annals of Internal Medicine.
Mortality risk was highest in patients who had both type 2 diabetes and ischemic heart disease and had not had previous revascularization.